dc.contributor.author | Cibrian, Danay | |
dc.contributor.author | Castillo-González, Raquel | |
dc.contributor.author | Fernández-Gallego, Nieves | |
dc.contributor.author | de la Fuente, Hortensia | |
dc.contributor.author | Jorge, Inmaculada | |
dc.contributor.author | Saiz, María Laura | |
dc.contributor.author | Punzón, Carmen | |
dc.contributor.author | Ramírez-Huesca, Marta | |
dc.contributor.author | Vicente-Manzanares, Miguel | |
dc.contributor.author | Fresno Escudero, Manuel | |
dc.contributor.author | Daudén Tello, Esteban | |
dc.contributor.author | Fraga-Fernández, Javier | |
dc.contributor.author | Vázquez, Jesús | |
dc.contributor.author | Aragonés López, Julián | |
dc.contributor.author | Sánchez Madrid, Francisco | |
dc.contributor.other | UAM. Departamento de Medicina | es_ES |
dc.contributor.other | Instituto de Investigación Sanitaria Hospital Universitario de La Princesa (IIS-IP) | es_ES |
dc.date.accessioned | 2020-11-10T17:27:44Z | |
dc.date.available | 2020-11-10T17:27:44Z | |
dc.date.issued | 2019-10-09 | |
dc.identifier.citation | Journal of Allergy and Clinical Immunology 145.1 (2020): 199-214.e11 | en_US |
dc.identifier.issn | 0091-6749 | es_ES |
dc.identifier.uri | http://hdl.handle.net/10486/692399 | |
dc.description.abstract | Background: Psoriasis is a frequent inflammatory skin disease that is mainly mediated by IL-23, IL-1β, and IL-17 cytokines. Although psoriasis is a hyperproliferative skin disorder, the possible role of amino acid transporters has remained unexplored. Objective: We sought to investigate the role of the essential amino acid transporter L-type amino acid transporter (LAT) 1 (SLC7A5) in psoriasis. Methods: LAT1 floxed mice were crossed to Cre-expressing mouse strains under the control of keratin 5, CD4, and retinoic acid receptor–related orphan receptor γ. We produced models of skin inflammation induced by imiquimod (IMQ) and IL-23 and tested the effect of inhibiting LAT1 (JPH203) and mammalian target of rapamycin (mTOR [rapamycin]). Results: LAT1 expression is increased in keratinocytes and skin-infiltrating lymphocytes of psoriatic lesions in human subjects and mice. LAT1 deletion in keratinocytes does not dampen the inflammatory response or their proliferation, which could be maintained by increased expression of the alternative amino acid transporters LAT2 and LAT3. Specific deletion of LAT1 in γδ and CD4 T cells controls the inflammatory response induced by IMQ. LAT1 deletion or inhibition blocks expansion of IL-17–secreting γ4+δ4+ and CD4 T cells and dampens the release of IL-1β, IL-17, and IL-22 in the IMQ-induced model. Moreover, inhibition of LAT1 blocks expansion of human γδ T cells and IL-17 secretion by human CD4 T cells. IL-23 and IL-1β stimulation upregulates LAT1 expression and induces mTOR activation in IL-17+ γδ and TH17 cells. Deletion or inhibition of LAT1 efficiently controls IL-23– and IL-1β–induced phosphatidylinositol 3-kinase/AKT/mTOR activation independent of T-cell receptor signaling. Conclusion: Targeting LAT1-mediated amino acid uptake is a potentially useful immunosuppressive strategy to control skin inflammation mediated by the IL-23/IL-1β/IL-17 axis. | en_US |
dc.description.sponsorship | Supported by grants SAF 2017-82886-R (to F.S.-M.), PI17/01972 (to E.D.), and SAF
2013-42850-R (to M.F.) from the Spanish Ministry of Economy and Competitiveness;
CAM (S2017/BMD-3671-INFLAMUNE-CM) from the Comunidad de Madrid (to
F.S.-M.); and CIBERCV, BIOIMID PIE13/041 from Instituto de Salud Carlos III
and Fundación La Marat o TV3 (20152330 31). The project leading to these results
has also received funding from FUNDACIóN BBVA A EQUIPOS DE INVESTIGACIÓN
CIENTÍFICA 2018 and from ‘‘la Caixa’’ Banking Foundation under the project code HR17-00016 (to F.S.-M.) and from Agencia Estatal de Investigación, Fondo Europeo de Desarrollo Regional, European Union | en_US |
dc.format.extent | 27 pag. | es_ES |
dc.format.mimetype | application/pdf | en |
dc.language.iso | eng | en_US |
dc.publisher | Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology. | en_US |
dc.relation.ispartof | Journal of Allergy and Clinical Immunology | en_US |
dc.rights | © 2019 The Authors | en_US |
dc.subject.other | L-type amino acid transporter 1 | en_US |
dc.subject.other | mammalian target of rapamycin | en_US |
dc.subject.other | psoriasis | en_US |
dc.subject.other | SLC7A5 | en_US |
dc.subject.other | T 17 H | en_US |
dc.subject.other | γδ T cells | en_US |
dc.title | Targeting L-type amino acid transporter 1 in innate and adaptive T cells efficiently controls skin inflammation | en_US |
dc.type | article | en |
dc.subject.eciencia | Medicina | es_ES |
dc.relation.publisherversion | https://doi.org/10.1016/j.jaci.2019.09.025 | es_ES |
dc.identifier.doi | 10.1016/j.jaci.2019.09.025 | es_ES |
dc.identifier.publicationfirstpage | 199 | es_ES |
dc.identifier.publicationissue | 1 | es_ES |
dc.identifier.publicationlastpage | 214.e11 | es_ES |
dc.identifier.publicationvolume | 145 | es_ES |
dc.relation.projectID | Gobierno de España. SAF 2017-82886-R | es_ES |
dc.relation.projectID | Gobierno de España. PI17/01972 | es_ES |
dc.relation.projectID | Gobierno de España. SAF 2013-42850-R | es_ES |
dc.relation.projectID | Comunidad de Madrid. S2017/BMD-3671/INFLAMUNE | es_ES |
dc.relation.projectID | Gobierno de España. PIE13/041 | es_ES |
dc.type.version | info:eu-repo/semantics/publishedVersion | en |
dc.rights.cc | Reconocimiento – NoComercial – SinObraDerivada | es_ES |
dc.rights.accessRights | openAccess | en |
dc.authorUAM | Aragonés López, Julián (261895) | |
dc.authorUAM | Cibrián Vera, Danay (264594) | |
dc.authorUAM | De La Fuente Flores, Hortensia (281227) | |
dc.authorUAM | Fernández-Gallego Anaya, Nieves (281307) | |
dc.authorUAM | Fresno Escudero, Manuel (259778) | |
dc.authorUAM | Sánchez Madrid, Francisco (259404) | |
dc.authorUAM | Daudén Tello, Esteban (259153) | |
dc.facultadUAM | Facultad de Medicina | |
dc.institutoUAM | Instituto de Investigación Sanitaria Hospital Universitario de La Princesa (IIS-Princesa) | |